Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $100.6 million.

  • Kiniksa Pharmaceuticals International's Total Current Liabilities rose 28.80% to $123.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.6 million, marking a year-over-year increase of 28.80%. This contributed to the annual value of $100.6 million for FY2024, which is 58.05% up from last year.
  • Kiniksa Pharmaceuticals International's Total Current Liabilities amounted to $100.6 million in FY2024, which was up 58.05% from $63.7 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Total Current Liabilities ranged from a high of $100.6 million in FY2024 and a low of $44.8 million during FY2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Total Current Liabilities value was $63.7 million (recorded in 2023), while the average stood at $70.5 million.
  • Data for Kiniksa Pharmaceuticals International's Total Current Liabilities shows a peak YoY skyrocketed of 58.05% (in 2024) over the last 5 years.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Total Current Liabilities (Yearly) stood at $44.8 million in 2021, then grew by 5.00% to $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then skyrocketed by 58.05% to $100.6 million in 2024.